STOCK TITAN

Agenus Inc - AGEN STOCK NEWS

Welcome to our dedicated news page for Agenus (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Agenus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Agenus's position in the market.

Rhea-AI Summary
Agenus completes patient enrollment in phase 2 trial for advanced colorectal cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
-
Rhea-AI Summary
Agenus Inc. to host corporate event at ESMO Conference to discuss advancements in its BOT/BAL program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
conferences
-
Rhea-AI Summary
Agenus grants inducement awards to new Chief Commercial Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Agenus Inc. CEO to participate in upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.34%
Tags
conferences
-
Rhea-AI Summary
Agenus Inc. announces strategic initiative to prioritize its BOT/BAL program, resulting in a workforce reduction of 25% and $40 million in savings by 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.28%
Tags
none
-
Rhea-AI Summary
Agenus Inc. (NASDAQ: AGEN) achieves a milestone in scaling the production of its STIMULON cultured plant cell (cpc) QS-21 adjuvant, designed to amplify the efficiency and endurance of vaccines. The breakthrough includes successful production of STIMULON cpcQS-21 with confirmed biochemical comparability to traditional bark extract-derived adjuvants. SaponiQx has submitted a Master File (MF) to the U.S. FDA, maintaining regulatory compliance. Ongoing collaboration with Ginkgo Bioworks aims to drive innovation in SaponiQx's adjuvant pipeline through generative molecular design.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.09%
Tags
-
Rhea-AI Summary
Agenus Inc. announced a data update for the phase 1 expansion cohort of botensilimab in combination with balstilimab for patients with advanced, refractory sarcomas. The update has been selected for an oral presentation at the upcoming ESMO Congress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.52%
Tags
none
-
Rhea-AI Summary
Agenus, an immuno-oncology leader, will release its Q2 2023 financial results on August 8, 2023. CEO Dr. Garo Armen will participate in the BTIG Virtual Biotechnology Conference on August 7, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
News
Rhea-AI Summary
Agenus Inc. (AGEN) appoints Robin Taylor, Ph.D. as Chief Commercial Officer, Homa Yeganegi as Chief Product Strategy and Global Medical Affairs Officer, and Stephanie Fagan as Chief Communications Officer. The new executives will drive the company's growth and the development of botensilimab and other immuno-oncology programs. Agenus plans to submit its first Biologics License Application to the U.S. FDA in 2024 for the approval of the combination in patients with refractory non-MSI-H metastatic colorectal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
management
Agenus Inc

Nasdaq:AGEN

AGEN Rankings

AGEN Stock Data

131.96M
17.69M
1.2%
59.18%
11.39%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Lexington

About AGEN

agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody